mitomycin has been researched along with Kahler Disease in 9 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple myeloma is an incurable hematological malignancy that relies on drug combinations for first and secondary lines of treatment." | 1.48 | Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). ( Chng, WJ; Chow, EK; Ho, CM; Ho, D; Hooi, L; Jha, S; Karnani, N; Rashid, MBMA; Silva, A; Tan, PF; Teh, AL; Toh, TB; Zhang, Y, 2018) |
| " There was a good correlation between ISCs and cytotoxicity in dose-response studies in each cell line." | 1.27 | Interactions of mitomycin C with mammalian DNA detected by alkaline elution. ( Alberts, DS; Bowden, GT; Dorr, RT; Liddil, JD, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Islam, I | 1 |
| Skibo, EB | 1 |
| Dorr, RT | 4 |
| Alberts, DS | 2 |
| Rashid, MBMA | 1 |
| Toh, TB | 1 |
| Hooi, L | 1 |
| Silva, A | 1 |
| Zhang, Y | 1 |
| Tan, PF | 1 |
| Teh, AL | 1 |
| Karnani, N | 1 |
| Jha, S | 1 |
| Ho, CM | 1 |
| Chng, WJ | 1 |
| Ho, D | 1 |
| Chow, EK | 1 |
| Paiva, B | 1 |
| Vidriales, MB | 1 |
| Cerveró, J | 1 |
| Mateo, G | 1 |
| Pérez, JJ | 1 |
| Montalbán, MA | 1 |
| Sureda, A | 1 |
| Montejano, L | 1 |
| Gutiérrez, NC | 1 |
| García de Coca, A | 1 |
| de Las Heras, N | 1 |
| Mateos, MV | 1 |
| López-Berges, MC | 1 |
| García-Boyero, R | 1 |
| Galende, J | 1 |
| Hernández, J | 1 |
| Palomera, L | 1 |
| Carrera, D | 1 |
| Martínez, R | 1 |
| de la Rubia, J | 1 |
| Martín, A | 1 |
| Bladé, J | 1 |
| Lahuerta, JJ | 1 |
| Orfao, A | 1 |
| San Miguel, JF | 1 |
| Barlogie, B | 1 |
| Epstein, J | 1 |
| Shaughnessy, JD | 1 |
| BERGSAGEL, DE | 2 |
| ROSS, SW | 1 |
| DAVIS, P | 1 |
| Adel, AL | 1 |
| Liddil, JD | 3 |
| Shipp, NG | 1 |
| Iyengar, BS | 1 |
| Kunz, KR | 1 |
| Remers, WA | 1 |
| Bowden, GT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Different Cardiorespiratory Training Program on Endurance Performance[NCT04357691] | 20 participants (Anticipated) | Interventional | 2020-05-25 | Not yet recruiting | |||
| Personalised, Rational, Efficacy-driven Cancer Drug Dosing Via an Artificial Intelligence SystEm - CURATE.AI (PRECISE CURATE.AI Trial)[NCT04522284] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2020-08-20 | Recruiting | ||
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)[NCT05381038] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-06-30 | Not yet recruiting | ||
| Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer[NCT05177432] | Phase 1 | 26 participants (Anticipated) | Interventional | 2021-12-06 | Recruiting | ||
| The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study[NCT03421132] | 250 participants (Anticipated) | Observational | 2018-02-20 | Recruiting | |||
| Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Resp[NCT00560053] | Phase 3 | 500 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mitomycin and Kahler Disease
8 other studies available for mitomycin and Kahler Disease
| Article | Year |
|---|---|
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
Topics: Alkylation; Antineoplastic Agents; Aziridines; Benzimidazoles; Colonic Neoplasms; DNA; Female; Free | 1991 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Depend | 2018 |
Going with the flow, and beyond, in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. II. Mitomycin C (NSC-26980).
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell- and Tissue-Based Therapy; Mitomycin; Multiple My | 1962 |
Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell- and Tissue-Based Therapy; Cycloleucine; Cyclopar | 1962 |
The effect of anticancer drug sequence in experimental combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Survival; Cisplatin; Drug Administra | 1993 |
Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Depression, Chemica | 1992 |
Interactions of mitomycin C with mammalian DNA detected by alkaline elution.
Topics: Alkylation; Animals; Cell Line; Cell Nucleus; Cell Survival; Cross-Linking Reagents; DNA, Neoplasm; | 1985 |